Stock Research: Teva Pharmaceutical Industries

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Teva Pharmaceutical Industries

NYSE:TEVA US8816242098
14
  • Value
    6
  • Growth
    13
  • Safety
    Safety
    30
  • Combined
    1
  • Sentiment
    89
  • 360° View
    360° View
    14
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Teva Pharmaceutical Industries Ltd. is an Israeli-based pharmaceutical company that manages a full product portfolio including generics, specialty, and over-the-counter (OTC) products, and also engages in selling active pharmaceutical ingredients (API) to third parties and contract manufacturing services. The company operates in North America, Europe, and International Markets. In the last fiscal year, the company had a market cap of $18517 million, profits of $8292 million, revenue of $16544 million, and 33892 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock Teva Pharmaceutical Industries are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Teva Pharmaceutical Industries. The consolidated Sentiment Rank has a good rank of 89, which means that professional investors are more optimistic about the stock than for 89% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 30, which means that the share price of Teva Pharmaceutical Industries is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 13, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 13% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 6 which means that the company has a riskier financing structure than 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Human Rights
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
30 60 77 78
Growth
13 40 31 15
Safety
Safety
6 12 6 4
Sentiment
89 37 36 6
360° View
360° View
14 28 12 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
83 72 26 17
Opinions Change
38 6 74 50
Pro Holdings
n/a 23 37 46
Market Pulse
85 67 49 17
Sentiment
89 37 36 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
30 60 77 78
Growth
13 40 31 15
Safety Safety
6 12 6 4
Combined
1 17 16 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
89 91 97 97
Price vs. Earnings (P/E)
52 59 87 97
Price vs. Book (P/B)
14 45 71 92
Dividend Yield
1 1 1 1
Value
30 60 77 78
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
8 21 8 16
Profit Growth
55 32 37 32
Capital Growth
16 51 49 51
Stock Returns
67 80 72 24
Growth
13 40 31 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
2 3 4 5
Refinancing
9 13 13 22
Liquidity
37 51 32 23
Safety Safety
6 12 6 4

Similar Stocks

Discover high‑ranked alternatives to Teva Pharmaceutical Industries and broaden your portfolio horizons.

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Continental

XTRA:CON
Country: Germany
Industry: Auto Parts & Equipment
Size: X-Large
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.